HIV-associated neurological disorders: a guide to pharmacotherapy (Q37971469)

26 August 2017

HIV-associated neurological disorders: a guide to pharmacotherapy (English)

1 reference

26 August 2017

0 references

Ik L Tan

1

1 reference

PubMed ID

22201342

26 August 2017

Justin C McArthur

series ordinal

2

1 reference

26 August 2017

1 February 2012

1 reference

26 August 2017

1 reference

26 August 2017

26

1 reference

26 August 2017

2

1 reference

26 August 2017

123-134

1 reference

https://scigraph.springernature.com/pub.10.2165/11597770-000000000-00000

26 August 2017

0 references

cites work

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Neurological complications of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Food combination and Alzheimer disease risk: a protective diet

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Updated research nosology for HIV-associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

HIV dementia: an evolving disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

HIV infection in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Variable benefit in neuropsychological function in HIV-infected HAART-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Benefit or toxicity from neurologically targeted antiretroviral therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

The impact of HIV-associated neuropsychological impairment on everyday functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Neurocognitive performance and quality of life in patients with HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Early viral brain invasion in iatrogenic human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Developments in HIV neuropathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

HIV-1 infection and cognitive impairment in the cART era: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

The neuropathogenesis of AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Mechanisms of neuroimmunity and neurodegeneration associated with HIV-1 infection and AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Human immunodeficiency virus encephalitis is the pathological correlate of dementia in acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Antiretroviral therapy and central nervous system HIV type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Cerebrospinal fluid neopterin concentrations in central nervous system infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

HIV disease: fallout from a mucosal catastrophe?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

The impact of systemic infection on the progression of neurodegenerative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Detection of Epstein-Barr virus in CNS lymphomas by in-situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Changing incidence of central nervous system diseases in the EuroSIDA cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Epidemiology of human immunodeficiency virus encephalopathy in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Effect of early versus deferred antiretroviral therapy for HIV on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Antiretroviral therapy in macrophages: implication for HIV eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Effects of hepatic function and hepatitis C virus on the nervous system assessment of advanced-stage HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection--The Hawaii Aging with HIV Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Pathogenesis of HIV in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Survival after neuroAIDS: Association with antiretroviral CNS Penetration-Effectiveness score

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

HIV pharmacology: barriers to the eradication of HIV from the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Antiretroviral therapy in HIV infection: are neurologically active drugs important?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

NanoART, neuroAIDS and CNS drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2'3'-dideoxycytidine (ddC).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Neuropsychiatric complications of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Human immunodeficiency virus in an aging population, a complication of success

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Immune reconstitution inflammatory syndrome and the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

A phase I/II trial of nimodipine for HIV-related neurologic complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Selegiline and oxidative stress in HIV-associated cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Human striatal activation reflects degree of stimulus saliency

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Efficacy of camptothecin in progressive multifocal leucoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Determinants of survival in progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Progressive multifocal leukoencephalopathy in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Lopinavir with Ritonavir Reduces the HIV RNA Level in Cerebrospinal Fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597770-000000000-00000

Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms.

21 January 2018

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders

1 reference

12 December 2020

Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group

1 reference

12 December 2020

HIV-associated central nervous system diseases in the era of combination antiretroviral therapy

1 reference

12 December 2020

HIV-associated neurocognitive disease continues in the antiretroviral era.

1 reference

12 December 2020

Cerebrospinal fluid beta 2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment

1 reference

12 December 2020

Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group

1 reference

12 December 2020

Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap

1 reference

12 December 2020

Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy

1 reference

12 December 2020

Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy

1 reference

12 December 2020

Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment

1 reference

12 December 2020

HIV infection of macrophages and pathogenesis of AIDS dementia complex: interaction of the host cell and viral genotype.

1 reference

12 December 2020

Cognitive dysfunction in HIV patients despite long-standing suppression of viremia

1 reference

12 December 2020

Viral myocarditis presenting with seizure and electrocardiographic findings of acute myocardial infarction in a 14-month-old child

1 reference

12 December 2020

Memantine for AIDS dementia complex: open-label report of ACTG 301.

1 reference

12 December 2020

Highly active antiretroviral therapy improves neurocognitive functioning

1 reference

12 December 2020

Neurologic complications of HIV disease and their treatment

1 reference

12 December 2020

The HNRC 500--neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center.

1 reference

12 December 2020

Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy

1 reference

12 December 2020

Adhering to complex regimens for HIV.

1 reference

12 December 2020

10.2165/11597770-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

22201342

Dimensions Publication ID

26 August 2017

0 references

1 reference

PubMed ID

22201342